The hypotheses on the pathophysiology of depression/mood disorders and on antidepressant mechanisms have greatly changed in recent years. The classical monoamine hypothesis was revealed to be simplistic, in that it could not explain the temporal delay in the therapeutic action of antidepressants. Converging lines of evidence have shown that adaptive changes in the several mechanisms of neuroplasticity are likely to be the cellular and molecular correlates of therapeutic effect. In this article, several mechanisms of neuroplasticity are analyzed in relation to the mechanism of antidepressants, ranging from changes in gene expression (including neurotrophic mechanisms), to synaptic transmission and plasticity, and neurogenesis. We propose that the current version of the hypothesis of antidepressant mechanism simply be called the "hypothesis of neuroplasticity." In the final section, we also briefly review the main current novel strategies in the pharmacology of depression and the new putative targets for antidepressants, with particular emphasis on non-monoaminergic mechanisms. Copyright

Cellular and molecular mechanisms in the long-term action of antidepressants / G. Racagni, M. Popoli. - In: DIALOGUES IN CLINICAL NEUROSCIENCE. - ISSN 1294-8322. - 10:4(2008), pp. 385-400.

Cellular and molecular mechanisms in the long-term action of antidepressants

G. Racagni
Primo
;
M. Popoli
Ultimo
2008

Abstract

The hypotheses on the pathophysiology of depression/mood disorders and on antidepressant mechanisms have greatly changed in recent years. The classical monoamine hypothesis was revealed to be simplistic, in that it could not explain the temporal delay in the therapeutic action of antidepressants. Converging lines of evidence have shown that adaptive changes in the several mechanisms of neuroplasticity are likely to be the cellular and molecular correlates of therapeutic effect. In this article, several mechanisms of neuroplasticity are analyzed in relation to the mechanism of antidepressants, ranging from changes in gene expression (including neurotrophic mechanisms), to synaptic transmission and plasticity, and neurogenesis. We propose that the current version of the hypothesis of antidepressant mechanism simply be called the "hypothesis of neuroplasticity." In the final section, we also briefly review the main current novel strategies in the pharmacology of depression and the new putative targets for antidepressants, with particular emphasis on non-monoaminergic mechanisms. Copyright
Antidepressant; BDNF; Circadian rhythm; CREB; Depression; Gene expression; Glutamate; Mood disorder; Neuroplasticity; NMDA receptor
Settore BIO/14 - Farmacologia
2008
http://www.dialogues-cns.org/brochures/39/htm/39_23.asp
Article (author)
File in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/62116
Citazioni
  • ???jsp.display-item.citation.pmc??? 38
  • Scopus 134
  • ???jsp.display-item.citation.isi??? ND
social impact